Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT07287644 is registered in ClinicalTrials.gov with Bluefin Biomedicine, Inc. as lead sponsor.

NCT NCT07287644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Bluefin Biomedicine, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 3, 2025
Completion date
August 1, 2027
Enrollment
210 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)